[go: up one dir, main page]

CY1106398T1 - 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες - Google Patents

6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες

Info

Publication number
CY1106398T1
CY1106398T1 CY20071100383T CY071100383T CY1106398T1 CY 1106398 T1 CY1106398 T1 CY 1106398T1 CY 20071100383 T CY20071100383 T CY 20071100383T CY 071100383 T CY071100383 T CY 071100383T CY 1106398 T1 CY1106398 T1 CY 1106398T1
Authority
CY
Cyprus
Prior art keywords
inflammatory cytokines
taken together
pyrazolo
pyrazole
dihydro
Prior art date
Application number
CY20071100383T
Other languages
English (en)
Inventor
Michael Philip Clark
Matthew John Laufersweiler
Jane Far-Jine Djung
Michael George Natchus
Biswanath De
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of CY1106398T1 publication Critical patent/CY1106398T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ενώσεις οι οποίες είναι ικανές να προλαμβάνουν την εξωκυτταρική απελευθέρωση φλεγμονωδών κυτοκινών, όπου οι εν λόγω ενώσεις, συμπεριλαμβανομένων όλων των εναντιομερικών και διαστερεομερικών μορφών και των φαρμακευτικώς αποδεκτών αλάτων τους, έχουν τον τύπο (I): στον οποίο το R περιλαμβάνει αιθέρες ή αμίνες, το R1 είναι: a) υποκατεστημένο ή μη υποκατεστημένο αρύλιο, ή b) υποκατεστημένο ή μη υποκατεστημένο ετεροαρύλιο, καθεμία μονάδα R?2¿ επιλέγεται ανεξαρτήτως από την ομάδα που αποτελείται από: a) υδρογόνο, b) -(CH¿2?)¿j?O(CH¿2?)nR?8¿, c) -(CH¿2?)¿j?NR?a¿R?9b¿, d) -(CH¿2?)¿-j?CO¿,2?R?10¿, e) -(CH¿2?)¿j?OCO?2¿R?10¿, f) -(CH¿2?)¿j?CON(R?10¿2?, g) -(CH¿,2?)¿j?OCON(R?10¿)¿2?, h) δύο μονάδες R?2¿, μπορούν να ληφθούν μαζί για να σχηματίσουν μια μονάδα καρβονυλίου, i) και μίγματά τους, τα R?8¿, R?9a¿, R?9b¿ και R?10¿ είναι το καθένα ανεξαρτήτως υδρογόνο, C¿1?-C¿4? αλκύλιο, και μίγματά τους, τα R?9a¿, και R?9b¿, μπορούν να ληφθούν μαζί για να σχηματίσουν ένα καρβοκυκλικό ή ετεροκυκλικό δακτύλιο που περιέχει από 3 έως 7 άτομα, δύο μονάδες R?10¿ μπορούν να ληφθούν μαζί για να σχηματίσουν ένα καρβοκυκλικό ή ετεροκυκλικό δακτύλιο που περιέχει από 3 έως 7 άτομα, το j είναι δείκτης από 0 έως 5, το n είναι δείκτης από 0 έως 5, το Ζ είναι Ο, S, NR?11¿, ή NOR?11¿, το R?1l¿ είναι υδρογόνο ή C¿1?-C¿4? αλκύλιο.
CY20071100383T 2001-09-20 2007-03-20 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες CY1106398T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32362501P 2001-09-20 2001-09-20
PCT/US2002/030135 WO2003024971A1 (en) 2001-09-20 2002-09-20 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Publications (1)

Publication Number Publication Date
CY1106398T1 true CY1106398T1 (el) 2011-10-12

Family

ID=23259997

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100383T CY1106398T1 (el) 2001-09-20 2007-03-20 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες

Country Status (32)

Country Link
US (2) US6821971B2 (el)
EP (3) EP1427732B1 (el)
JP (3) JP2005504083A (el)
KR (4) KR100623879B1 (el)
CN (3) CN1250551C (el)
AR (3) AR037502A1 (el)
AT (3) ATE287887T1 (el)
AU (2) AU2002327690B2 (el)
BR (3) BR0212905A (el)
CA (3) CA2461071A1 (el)
CO (3) CO5560589A2 (el)
CY (1) CY1106398T1 (el)
CZ (3) CZ2004358A3 (el)
DE (3) DE60213108T2 (el)
DK (2) DK1427732T3 (el)
EG (2) EG24363A (el)
ES (3) ES2282459T3 (el)
HU (3) HUP0402378A3 (el)
IL (3) IL160682A0 (el)
MA (3) MA27064A1 (el)
MX (3) MXPA04002570A (el)
MY (2) MY129069A (el)
NO (2) NO20041594L (el)
NZ (3) NZ531123A (el)
PE (3) PE20030446A1 (el)
PL (3) PL370351A1 (el)
PT (3) PT1427732E (el)
RU (3) RU2272040C2 (el)
SA (1) SA03230529B1 (el)
SK (3) SK1482004A3 (el)
WO (3) WO2003024971A1 (el)
ZA (3) ZA200401260B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087615B2 (en) 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US6849627B2 (en) 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
ES2283811T3 (es) * 2002-09-09 2007-11-01 Amgen Inc. Derivados de 1,2-dihidro-pirazol-3-ona y 3-alcoxi-1h-pirazol sustituidos 1,4,5- para la utilizacion como agentes reductores de tnf-alfa e interleukina en el tratamiento de inflamaciones.
MXPA05010445A (es) * 2003-04-03 2005-11-04 Merck Patent Gmbh Derivados de azaprolina.
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
CN101426498A (zh) * 2006-04-18 2009-05-06 艾博特公司 香草素受体亚型1(vr1)的拮抗剂及其用途
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
DK2432767T3 (da) * 2009-05-19 2013-09-30 Dow Agrosciences Llc Forbindelser og fremgangsmåder til at kontrollere svampe
WO2016205284A1 (en) 2015-06-15 2016-12-22 Cummins Inc. Combustion chamber elasticity device
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN107033090B (zh) * 2017-05-16 2019-05-07 无锡捷化医药科技有限公司 一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) * 2019-09-06 2020-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
US20240425524A1 (en) * 2021-10-27 2024-12-26 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054291A (el) * 1963-02-26
GB1124982A (en) * 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529154A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) * 1991-03-21 1994-10-25 Bayer Aktiengesellschaft 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
CA2133963C (en) * 1992-05-15 1998-07-07 Gary A. Flynn Novel mercaptoacetylamido pyridazo[1,2]pyridazine, pyrazolo[1,2]pyridazine, pyridazo[1,2-a][1,2]diazepine and pyrazolo[1,2-a][1,2]diazepine derivatives useful as inhibitors of enkephalinase and ace
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
CA2382435C (en) * 1999-09-07 2009-02-03 Syngenta Participations Ag Novel herbicidally active phenyl-substituted heterocycles
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
RU2278864C2 (ru) 2006-06-27
PT1427732E (pt) 2006-12-29
DE60218704D1 (de) 2007-04-19
BR0212905A (pt) 2004-10-13
BR0212673A (pt) 2004-08-24
ATE287887T1 (de) 2005-02-15
CA2461071A1 (en) 2003-03-27
DE60213108D1 (de) 2006-08-24
HK1071366A1 (en) 2005-07-15
IL160742A0 (en) 2004-08-31
CN1555379A (zh) 2004-12-15
ZA200401260B (en) 2004-08-30
PL370351A1 (en) 2005-05-16
PT1427728E (pt) 2007-05-31
DK1427728T3 (da) 2007-07-09
US6821971B2 (en) 2004-11-23
DE60218704T2 (de) 2007-11-08
IL160682A0 (en) 2004-08-31
AR037237A1 (es) 2004-11-03
PL370415A1 (en) 2005-05-30
AR037502A1 (es) 2004-11-17
CO5560590A2 (es) 2005-09-30
PL370362A1 (en) 2005-05-16
EG24413A (en) 2009-05-25
DE60202782T2 (de) 2006-01-19
HUP0402500A2 (hu) 2005-03-29
ES2268154T3 (es) 2007-03-16
DE60202782D1 (de) 2005-03-03
ATE332901T1 (de) 2006-08-15
WO2003024971A1 (en) 2003-03-27
PT1427727E (pt) 2005-06-30
MA27066A1 (fr) 2004-12-20
MY129069A (en) 2007-03-30
PE20030446A1 (es) 2003-07-21
CA2461073A1 (en) 2003-03-27
RU2004111805A (ru) 2005-04-10
BR0212716A (pt) 2004-08-03
MY129329A (en) 2007-03-30
DE60213108T2 (de) 2007-02-08
AU2002327690B2 (en) 2006-07-20
WO2003024973A1 (en) 2003-03-27
HUP0402500A3 (en) 2008-10-28
DK1427732T3 (da) 2006-10-30
CN1555375A (zh) 2004-12-15
ZA200401403B (en) 2004-08-30
KR100656126B1 (ko) 2006-12-12
KR20040035837A (ko) 2004-04-29
MA27064A1 (fr) 2004-12-20
JP2005504083A (ja) 2005-02-10
ATE356126T1 (de) 2007-03-15
MXPA04002570A (es) 2004-05-31
SK1482004A3 (en) 2004-08-03
EG24363A (en) 2009-03-04
JP2005504081A (ja) 2005-02-10
RU2004111806A (ru) 2005-03-27
HK1071565A1 (en) 2005-07-22
CN1257905C (zh) 2006-05-31
PE20030474A1 (es) 2003-07-22
NO20041605L (no) 2004-06-21
SK1492004A3 (en) 2004-11-03
MXPA04002574A (es) 2004-06-18
WO2003024970A1 (en) 2003-03-27
US6566357B1 (en) 2003-05-20
SK1502004A3 (en) 2004-09-08
PE20030430A1 (es) 2003-06-24
ES2282459T3 (es) 2007-10-16
RU2299885C2 (ru) 2007-05-27
JP2005504082A (ja) 2005-02-10
NZ531063A (en) 2007-08-31
US20030105084A1 (en) 2003-06-05
HUP0402378A2 (hu) 2005-02-28
ZA200401402B (en) 2004-08-27
EP1427732A1 (en) 2004-06-16
CZ2004345A3 (cs) 2004-06-16
CN1250551C (zh) 2006-04-12
KR20060036125A (ko) 2006-04-27
MXPA04002569A (es) 2004-05-31
KR20040035836A (ko) 2004-04-29
EP1427732B1 (en) 2006-07-12
HUP0402378A3 (en) 2008-10-28
NZ531122A (en) 2005-09-30
EP1427728B1 (en) 2007-03-07
KR100623879B1 (ko) 2006-09-19
CZ2004358A3 (cs) 2004-07-14
RU2004111803A (ru) 2005-10-10
KR20040035835A (ko) 2004-04-29
EP1427727B1 (en) 2005-01-26
AU2002334641B2 (en) 2007-03-29
MA27065A1 (fr) 2004-12-20
EP1427728A1 (en) 2004-06-16
CN1249066C (zh) 2006-04-05
EP1427727A1 (en) 2004-06-16
NZ531123A (en) 2006-08-31
CN1556811A (zh) 2004-12-22
ES2237691T3 (es) 2005-08-01
CO5560579A2 (es) 2005-09-30
IL160741A0 (en) 2004-08-31
CZ2004361A3 (cs) 2004-07-14
SA03230529B1 (ar) 2008-06-21
HUP0500752A2 (en) 2006-01-30
CO5560589A2 (es) 2005-09-30
CA2461072A1 (en) 2003-03-27
NO20041594L (no) 2004-06-21
AR037145A1 (es) 2004-10-27
RU2272040C2 (ru) 2006-03-20

Similar Documents

Publication Publication Date Title
CY1106398T1 (el) 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες
MXPA02011977A (es) Herbicidas de piridina sustituidas.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ATE116295T1 (de) Perhydroisoindol derivate und ihre herstellung.
DK1382604T3 (da) Quinolinderivater med en azolylgruppe og quinazolinderivater
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
SG161302A1 (en) DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE ss2 ADRENERGIC RECEPTOR
DE50311885D1 (de) Kohlenstoffhaltiges Material
DE69434136D1 (de) Dolastatin-derivate
ES8400388A1 (es) Metodo de preparar compuestos aminoalcoil heterociclicos de de actividad farmaceutica.
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
AR010080A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno
ATE296300T1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DE60011269D1 (de) Azaidole mit serotonin rezeptor affinität
WO2001023392A8 (en) Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
TW200510320A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
WO2005028489A3 (en) Novel adenosine a3 receptor agonists
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
HRP20030381B1 (en) 3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors
DE60103752D1 (de) Verfahren zur herstellung von pyrazolopyridinderivaten
YU25699A (sh) Novi derivati eritromicina, postupak za njihovu izradu i njihova primena